174 related articles for article (PubMed ID: 20950443)
1. The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells.
Schult C; Dahlhaus M; Ruck S; Sawitzky M; Amoroso F; Lange S; Etro D; Glass A; Fuellen G; Boldt S; Wolkenhauer O; Neri LM; Freund M; Junghanss C
BMC Cancer; 2010 Oct; 10():560. PubMed ID: 20950443
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
Yu C; Friday BB; Lai JP; Yang L; Sarkaria J; Kay NE; Carter CA; Roberts LR; Kaufmann SH; Adjei AA
Mol Cancer Ther; 2006 Sep; 5(9):2378-87. PubMed ID: 16985072
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.
Katz SI; Zhou L; Chao G; Smith CD; Ferrara T; Wang W; Dicker DT; El-Deiry WS
Cancer Biol Ther; 2009 Dec; 8(24):2406-16. PubMed ID: 20038816
[TBL] [Abstract][Full Text] [Related]
4. Synergistic activity of letrozole and sorafenib on breast cancer cells.
Bonelli MA; Fumarola C; Alfieri RR; La Monica S; Cavazzoni A; Galetti M; Gatti R; Belletti S; Harris AL; Fox SB; Evans DB; Dowsett M; Martin LA; Bottini A; Generali D; Petronini PG
Breast Cancer Res Treat; 2010 Nov; 124(1):79-88. PubMed ID: 20054642
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways.
Oh SJ; Erb HH; Hobisch A; Santer FR; Culig Z
Endocr Relat Cancer; 2012 Jun; 19(3):305-19. PubMed ID: 22383427
[TBL] [Abstract][Full Text] [Related]
6. A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers.
Cohen SM; Mukerji R; Timmermann BN; Samadi AK; Cohen MS
Am J Surg; 2012 Dec; 204(6):895-900; discussion 900-1. PubMed ID: 23231932
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways.
Wei G; Wang M; Carr BI
J Cell Physiol; 2010 Jul; 224(1):112-9. PubMed ID: 20301194
[TBL] [Abstract][Full Text] [Related]
8. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation.
Rahmani M; Davis EM; Bauer C; Dent P; Grant S
J Biol Chem; 2005 Oct; 280(42):35217-27. PubMed ID: 16109713
[TBL] [Abstract][Full Text] [Related]
9. The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cells.
Huang R; Chen XQ; Huang Y; Chen N; Zeng H
Asian J Androl; 2010 Jul; 12(4):527-34. PubMed ID: 20473320
[TBL] [Abstract][Full Text] [Related]
10. Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.
Hu S; Niu H; Inaba H; Orwick S; Rose C; Panetta JC; Yang S; Pounds S; Fan Y; Calabrese C; Rehg JE; Campana D; Rubnitz JE; Baker SD
J Natl Cancer Inst; 2011 Jun; 103(11):893-905. PubMed ID: 21487100
[TBL] [Abstract][Full Text] [Related]
11. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
Rosato RR; Almenara JA; Coe S; Grant S
Cancer Res; 2007 Oct; 67(19):9490-500. PubMed ID: 17909059
[TBL] [Abstract][Full Text] [Related]
12. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas.
Yang F; Van Meter TE; Buettner R; Hedvat M; Liang W; Kowolik CM; Mepani N; Mirosevich J; Nam S; Chen MY; Tye G; Kirschbaum M; Jove R
Mol Cancer Ther; 2008 Nov; 7(11):3519-26. PubMed ID: 19001435
[TBL] [Abstract][Full Text] [Related]
14. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F
Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806
[TBL] [Abstract][Full Text] [Related]
15. Fluvastatin enhances sorafenib cytotoxicity in melanoma cells via modulation of AKT and JNK signaling pathways.
Zhang S; Doudican NA; Quay E; Orlow SJ
Anticancer Res; 2011 Oct; 31(10):3259-65. PubMed ID: 21965734
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis.
Yang F; Jove V; Buettner R; Xin H; Wu J; Wang Y; Nam S; Xu Y; Ara T; DeClerck YA; Seeger R; Yu H; Jove R
Cancer Biol Ther; 2012 May; 13(7):534-41. PubMed ID: 22406995
[TBL] [Abstract][Full Text] [Related]
17. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Koch A; Evers BM
Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
[TBL] [Abstract][Full Text] [Related]
18. Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis.
Hennenberg M; Trebicka J; Kohistani Z; Stark C; Nischalke HD; Krämer B; Körner C; Klein S; Granzow M; Fischer HP; Heller J; Sauerbruch T
Lab Invest; 2011 Feb; 91(2):241-51. PubMed ID: 20921950
[TBL] [Abstract][Full Text] [Related]
19. Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells.
Sugiyama H; Onuki K; Ishige K; Baba N; Ueda T; Matsuda S; Takeuchi K; Onodera M; Nakanuma Y; Yamato M; Yamamoto M; Hyodo I; Shoda J
J Gastroenterol; 2011 Jun; 46(6):779-89. PubMed ID: 21331764
[TBL] [Abstract][Full Text] [Related]
20. The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells.
Niessner H; Beck D; Sinnberg T; Lasithiotakis K; Maczey E; Gogel J; Venturelli S; Berger A; Mauthe M; Toulany M; Flaherty K; Schaller M; Schadendorf D; Proikas-Cezanne T; Schittek B; Garbe C; Kulms D; Meier F
J Invest Dermatol; 2011 Feb; 131(2):468-79. PubMed ID: 20944654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
